Skip to content
Search AI Powered

Latest Stories

'Durvalumab' can improve life span of lung cancer patients

The drug, ‘durvalumab’, can double the overall time someone can survive with an aggressive form of lung cancer from two-and-a-half to five years.

It has been approved by the National Institute for Health and Care Excellence (NICE) and the NHS has sealed a deal with manufacturer AstraZeneca to begin rolling it out.


The new treatment will be offered to more than 550 patients a year with advanced non-small-cell lung cancer (NSCLC) who have already undergone both chemotherapy and radiotherapy concurrently.

NHS said: “The drug can stop the cancer from getting worse for more than two years – significantly longer than treatment with a combination of chemotherapy and radiotherapy, which can only hold the disease at bay for around six months. This increases overall survival time and gives patients more precious moments with their loved ones.”

Dame Cally Palmer, national cancer director for NHS England, said: “We are resolute in our ambition to fight the devastating effects of cancer and new pioneering treatments like durvalumab are a vital lifeline for people living with cancer – giving them more precious time with family and friends.

“Most of us know someone who has been diagnosed with cancer and it can affect people of all walks of life. The NHS has continued to prioritise cancer care throughout the pandemic and I urge anyone with concerns about symptoms they might be experiencing to come forward without delay and get checked, either at your GP or at one of our mobile lung cancer scanning units”.

AstraZeneca's Durvalumab was previously offered to NHS patients in 2019 through the Cancer Drugs Fund to enable further data to be collected on the drug’s clinical and cost effectiveness.

This additional data has enabled NICE to make a final recommendation this week on its routine use in the NHS. In just over five years, more than 80,000 patients have benefitted from faster access to one of more than 90 different cancer drugs.

Durvalumab is the latest in a series of new treatments for lung cancer made available for NHS patients, including revolutionary ‘death star’ mutation drug, sotorasib, the targeted tablet treatment, mobocertinib, and new immunotherapy, atezolizumab; all of which were fast-tracked to NHS patients following agreements reached with individual pharmaceutical companies.

More For You

The Complete Anti-Inflammatory Guide - a useful resource for pharmacists to support patient health and wellbeing

Chronic inflammation is linked to more than 50 per cent of all deaths worldwide and one in five cancers.

The Complete Anti-Inflammatory Guide - a useful resource for pharmacists to support patient health and wellbeing

When Hemant Patel was struck down by Covid, he was determined to discover what was it that led to the disease having a devastating impact on the lives of people who seemed be healthy – the culmination of his journey is the book, The Complete Anti-Inflammatory Guide.

“I was gasping for breath and counting the number of days I might be alive when I was infected with Covid,” reveals Patel.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less